In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on MyoKardia Inc (MYOK – Research Report), with a price target of $73. The company’s shares closed last Monday at $55.25.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 22.7% and a 48.8% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, Madrigal Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
Currently, the analyst consensus on MyoKardia Inc is a Strong Buy with an average price target of $78.
Based on MyoKardia Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $38.17 million. In comparison, last year the company had a GAAP net loss of $18.41 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases.